Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) - Nov 13, 2024 - "Recent Business Highlights and Select Anticipated Milestones - Luveltamab Tazevibulin (luvelta), FRα-Targeting ADC Franchise:...(i) An expansion study of...the Phase 1b study of luvelta in combination with bevacizumab for patients with ovarian cancer...is ongoing, with data expected in the first half of 2025; (ii) A Phase 2 trial for the treatment of NSCLC is underway, with initial data expected in 2025."
P1 data • P2 data • Non Small Cell Lung Cancer • Ovarian Cancer
|